Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Novo Nordisk (NVO), the company behind popular diabetes and weight loss medications Ozempic and Wegovy, warned that President ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is ...

Under government rules, the listing allowed compounding pharmacies to make their own, cheaper versions and spawned an alternative marketplace for off-brand weight-loss drugs. Now Novo Nordisk and ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

In addition to competing with compounding pharmacies, Novo Nordisk must compete with tirzepatide from Eli Lilly (NYSE: LLY). The FDA approved Lilly's GLP-1 drug, tirzepatide, under the brand name ...